Navigation Links
Nanomedical Diagnostics Agile R100 Graphene Biosensor Characterizes Difficult-to-Study MYC Oncoprotein for Cancer Research
Date:8/7/2018

Nanomedical Diagnostics, leading manufacturer of graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces a new publication titled, “Synthetic Molecules for Disruption of the Myc Protein-Protein Interface” in the Elsevier journal Bioorganic & Medicinal Chemistry. The paper prominently features use of Agile R100, described as a “field-effect transistor (Bio-FET) platform,” to produce a new lead compound of significantly increased in vivo stability and solubility.

MYC is a prominent regulator gene that is a recognized actor in cancer initiation and maintenance, and thus a promising target for anti-cancer drugs. An intrinsically disordered protein, MYC can bind nonspecifically to and aggregate on dextran surfaces, making small molecule interaction studies for this “undruggable target” difficult to perform using traditional platforms. Agile R100 biosensors employ graphene surfaces that reduce nonspecific binding and enable direct binding measurements of challenging proteins such as MYC.

The paper describes the development of a screening platform incorporating Agile R100 as part of a blind structure-activity-relationship (SAR) study. “Our first attempts to characterize the interactions of MYC by surface plasmon resonance (SPR) gave us too high of a background due to non-specific interactions of the protein with the chip surface,” says Dr. Nicholas Jacob, lead author of the study. “In contrast, Agile R100’s graphene surface proved significantly less prone to these nonspecific interactions, and we were able to achieve a higher signal-to-noise ratio. The system allowed us to measure affinities for small molecule interactions with MYC in a label-free manner where other standard methods had failed.”

In the study, binding data from Agile R100 correlated well with data from in vivo microtumor formation inhibition assays using chicken embryo fibroblasts (CEF), as opposed to SPR data, which did not. The publication goes on to reference additional advantages of Agile R100: The system has a much lower limit of detection than SPR or isothermal calorimetry (ITC), and its site-specific functionalization decreased aggregation on the chip which further reduced nonspecific noise.

Agile R100 is a novel optics-free binding assay platform for the kinetic characterization of biomolecular interactions. As a graphene biosensor, Agile R100 monitors changes in electrical conductivity to gain sensitive label-free measurements, enabling real-time quantitative analysis of difficult-to-study molecules. “Agile R100 uses a novel electrical sensing mechanism that enables researchers to characterize difficult, disordered targets with less time and resources,” says Nanomedical Diagnostics CEO, Ross Bundy. “This is the first step towards understanding the biological pathways of historically undruggable targets like MYC, unlocking new opportunities for future cancer therapies.”

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive label-free kinetic characterization of biomolecular interactions for accelerated drug discovery. As the world’s leading developer and manufacturer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

Read the full story at https://www.prweb.com/releases/nanomedical_diagnostics_agile_r100_graphene_biosensor_characterizes_difficult_to_study_myc_oncoprotein_for_cancer_research/prweb15675304.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
2. OncoPlex Diagnostics Announces the Addition of the Androgen Receptor Protein to Their Quantitative Breast Cancer Proteomic Panel
3. Kalorama Report: Sizable Number of Acquisitions and Joint Ventures in Molecular Diagnostics
4. MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors
5. handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities
6. Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2015 to 2019
7. Force Diagnostics and higi Partner to Provide Innovative Services to Life Insurance Industry:
8. Singulex and Thermo Fisher Scientific Enter into License and Supply Agreement to bring Next Generation Immunodiagnostics to Sepsis and SIRS Diagnostics
9. Heart Health Innovator Boston Heart Diagnostics Joins American College of Lifestyle Medicine Corporate Roundtable
10. Green photon beams more agile than optical tweezers
11. Global Cancer Biomarkers Market 2012-2016 with Agilent Technologies Inc., Gen-Probe Inc. and Astellas Pharma US Inc. Dominating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2018)... DENVILLE, N.J. (PRWEB) , ... ... ... leading global provider for complete solutions for sample preparation and epigenetics research, ... late last year from the Research Center of Molecular Medicine of the ...
(Date:9/27/2018)... ... September 26, 2018 , ... ... Riley, Ph.D. has joined the organization in the role of Chief Scientific Officer ... of Chief Scientific Officer is transitioning to Chief Medical Officer. , The ...
(Date:9/24/2018)... ... 2018 , ... EDETEK, the premier provider of digital clinical ... for Clinical Data Management (SCDM) 2018 Annual Conference taking place in Seattle, WA ... Innovations in Boston, MA on September 25-26, 2018. , At both events, ...
Breaking Biology News(10 mins):
(Date:9/27/2018)... ... September 27, 2018 , ... Global molecular diagnostics company, ... Holotype HLA and other Omixon products will be featured among nine posters produced ... Histocompatibility and Immunogenetics (ASHI) in Baltimore, MD. Additionally, Omixon’s Lunch Symposium ...
(Date:9/22/2018)... Colo. (PRWEB) , ... September ... ... Biosciences are excited to announce a strategic venture. The synergistic combination of ... platform provides complimentary and comprehensive biomarker profiling to empower clinical trials in ...
(Date:9/22/2018)... ... September 21, 2018 , ... ... phenotypes in tissue function, development, and pathogenesis requires tools that can rapidly ... , Multiplexed Ion Beam Imaging by Time-Of-Flight (MIBI-TOF) detects elements from ...
(Date:9/15/2018)... ... ... Nationally recognized public accounting and consulting firm Cherry Bekaert LLP ... Nashville practice, on her appointment to Launch Tennessee’s Board of Directors. , ... of the Firm’s Nashville practice in December 2017 . In this role, she oversees ...
Breaking Biology Technology: